In this episode, we feature Plenary Lecture 04 from the AD/PD™ 2025 International Conference — the Eric N. Birch Memorial Lecture, titled “Treatment of DLB and PDD: Status and New Developments.”
Chaired by Dr. Sandra Moose (USA) and presented by Prof. Dag Aarsland (UK), this important plenary cast a spotlight on two often-overlooked conditions in the neurodegenerative disease landscape: Dementia with Lewy Bodies (DLB) and Parkinson’s Disease Dementia (PDD).
Prof. Aarsland delivered a comprehensive update on the therapeutic landscape of Lewy body dementia, both current standards and promising directions in the pipeline.
Key highlights include:
• The persistent underdiagnosis and underfunding of Lewy body dementia research, despite its high prevalence
• An overview of current evidence-based treatments, including cholinesterase inhibitors and Pimavanserin for psychosis
• A review of ongoing and recent drug trials — including Neflamapimod, CT1812, Ambroxol, and Dantrolene
• The importance of repurposed drugs and symptom management toolkits like the Diamond Lewy Toolkit
• The emerging role of non-pharmacological approaches such as cortical stimulation
• New directions in biomarker-based stratification for targeted therapies
• A call for better trial designs and increased research collaboration in the DLB/PDD space
This episode is especially relevant for neurologists, clinical researchers, drug developers, healthcare policymakers, and advocacy groups working to improve outcomes for people living with Lewy body and Parkinson’s-related dementias.
This podcast was created using AI to provide a quick and insightful summary of an AD/PD™ 2025 session. While every effort has been made to ensure accuracy, listeners are encouraged to refer to original conference materials and recordings for detailed information.
The AD/PD™ 2025 International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders, took place on April 1-5, 2025, in Vienna Austria.
https://adpd.kenes.com/